| Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin JW Vandiver, TG Vondracek Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32 (6 …, 2012 | 223 | 2012 |
| How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for … EJ Favaloro, G Kershaw, S Mohammed, G Lippi Seminars in thrombosis and hemostasis 45 (01), 022-035, 2019 | 99 | 2019 |
| Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations JW Vandiver, LI Ritz, JT Lalama Journal of thrombosis and thrombolysis 41, 475-481, 2016 | 64 | 2016 |
| Assessing an enoxaparin dosing protocol in morbidly obese patients JT Lalama, ME Feeney, JW Vandiver, KD Beavers, LN Walter, ... Journal of thrombosis and thrombolysis 39, 516-521, 2015 | 44 | 2015 |
| Severe hyponatremia and immune nephritis following an initial infusion of nivolumab JW Vandiver, Z Singer, C Harshberger Targeted oncology 11, 553-556, 2016 | 35 | 2016 |
| A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring JW Vandiver, TG Vondracek Hospital practice 41 (2), 16-24, 2013 | 28 | 2013 |
| Transitions of Care in Medical Education: A Compilation of Effective Teaching Methods. M McBryde, JW Vandiver, M Onysko Family medicine 48 (4), 265-272, 2016 | 25 | 2016 |
| Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection JW Vandiver, K Diane Beavers Journal of Thrombosis and Thrombolysis 45, 423-431, 2018 | 11 | 2018 |
| Comparison of continuation of low-molecular-weight heparin versus switching to unfractionated heparin in the peripartum CA Enakpene, KN Pontarelli, M Della Torre American Journal of Perinatology 37 (03), 304-312, 2020 | 4 | 2020 |
| Clostridium perfringens as an unusual cause of a prosthetic joint infection following total knee arthroplasty G Stroud, JW Vandiver IDCases 20, e00789, 2020 | 4 | 2020 |
| Periprocedural management of oral anticoagulation: When and how to hit “pause” N Hlavacek, D McMillan, J Vandiver J Fam Pract 67, 210-22, 2018 | 3 | 2018 |
| Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic N Arlas, JW Vandiver Journal of Clinical and Translational Endocrinology: Case Reports 23, 100109, 2022 | 2 | 2022 |
| It's time to rethink your approach to C diff infection. K Zukauckas, J Vandiver, L Biehle The Journal of Family Practice 69 (6), 293-300, 2020 | 2 | 2020 |
| Statin adverse effects: sorting out the evidence W Vandiver, ML Hunter Fam Pract 62, 730, 2013 | 2 | 2013 |
| Oral antivirals for high-risk COVID-19 patients L Biehle, JW Vandiver US Pharmacist 47 (7), 34-40, 2022 | 1 | 2022 |
| Perceptions of programs that orient non-practice faculty to the pharmacy profession: A pilot study JT Lamberts, JW Vandiver, KK Daugherty, MV DiVall, L Lebovitz, ... Currents in Pharmacy Teaching and Learning 13 (7), 812-818, 2021 | 1 | 2021 |
| Strengthening Student Success: Investing in the Future of Pharmacy at University of Wyoming Through Wellness EM Sogol, J Hornecker, ML Balkely, ML Hilaire, TD Mahvan, AB Oung, ... American Journal of Pharmaceutical Education 87 (8), 2023 | | 2023 |
| Hyponatraemia and immune nephritis: case report JW Vandiver Reactions 1616, 118-27, 2016 | | 2016 |
| Is a novel anticoagulant right for your patient? JW Vandiver, D Faulkner, M Erlandson, M Onysko Journal of Family Practice 63 (1), 22-29, 2014 | | 2014 |
